Revenue segments as reported by the company.

Dialysis patient service revenues

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

General and administrative

Depreciation and amortization

Equity investment income (loss), net

Loss (gain) on changes in ownership interest, net

Goodwill impairment charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

DaVita

DaVita, Inc. engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure. The Other-Ancillary Services and Strategic Initiatives segment consist primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care, end stage renal disease seamless care organizations, and comprehensive care. The company was founded in 1994 and is headquartered in Denver, CO.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

DaVita reports robust Q4 earnings, navigates challenges with strategic focus

DaVita's Q4 2022 performance reflects financial strength and operational improvements, supported by strategic initiatives and cost discipline.
While facing challenges in operational dynamics and market uncertainties, DaVita remains focused on growth opportunities and patient-centric care.
The company's outlook for 2023 shows a commitment to long-term success through innovation, efficiency, and resilience in a changing healthcare landscape.

DaVita reports strong Q1 earnings and innovation in kidney health

DaVita's Q1 2023 earnings call highlighted strong financial performance, operational efficiency, and a focus on patient care, positioning the company well for future growth and success.
While challenges such as limited operational details and potential labor management issues exist, DaVita's strengths in cost management, innovation, and patient-centric care present opportunities for sustained performance.
Overall, DaVita's positive momentum, revised financial outlook, and commitment to enhancing healthcare services indicate a promising trajectory for the company in the competitive healthcare landscape.

DaVita reports strong Q2 earnings, navigates CMS challenges effectively

DaVita's Q2 2023 performance reflects resilience amidst challenges, with a focus on innovation and operational efficiencies.
The company faces industry headwinds but remains committed to driving growth and enhancing patient care.
Analysts' questions highlighted key concerns and opportunities, showcasing DaVita's proactive approach to addressing industry dynamics.
Overall, DaVita's strategic focus on performance and stakeholder communication positions the company for continued success.

DaVita reports robust Q3 performance and eyes growth opportunities

DaVita's Q3 2023 Earnings Call highlighted strong financial results, operational priorities, and growth prospects. Despite challenges in managing drug impacts and market perception, the company remains focused on delivering quality care and driving shareholder value. Opportunities in CKD progression, shareholder returns, and IKC business improvement position DaVita for future success.

DaVita surpasses 2023 guidance, eyes growth and efficiency in 2024

DaVita's Q4 2023 Earnings Call showcased strong financial performance, exceeding guidance and highlighting a focus on efficiency and cost savings.
While facing challenges like legal proceedings and capacity utilization, DaVita remains optimistic about financial recovery and growth opportunities in 2024.
The company's successful Integrated Kidney Care program and commitment to driving operating performance position it well for continued success in the healthcare market.

DaVita reports robust Q1 earnings, eyes international expansion opportunities

DaVita's Q1 2024 performance reflects strong financial results and a strategic focus on kidney care solutions and international growth.
While challenges like the Change Healthcare outage were addressed, opportunities in expanding markets and enhancing patient care services are evident.
Management's commitment to quality care and sustainable growth positions DaVita well for continued success in the healthcare sector.

DaVita reports robust Q2 earnings, supports CMS proposal for growth

DaVita's Q2 2024 earnings call highlighted strong financial performance and strategic initiatives to drive growth.
While facing challenges in certain operational areas, the company's proactive stance on policy advocacy and financial guidance raise optimism.
Opportunities lie in optimizing operational metrics, managing costs effectively, and engaging stakeholders for sustained growth.

DaVita maintains financial course amidst challenges, eyes growth opportunities

DaVita's Q3 performance met expectations despite supply chain disruptions, with full-year guidance reaffirmed.
The company faces short-term challenges from hurricane impacts and regulatory uncertainties.
Opportunities lie in market changes and growth initiatives, though long-term guidance remains pending.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amedisys

Garmin

Ultra Clean

Top Ranked Momentum Stocks to Buy for November 22nd

CRA International

First American Financial

NRG Energy

Quanta Services

A strong rally is unlikely for as long as this trade conflict continues. However, the downside potential will be limited owing to U.S.

Shrug Off Market Gyrations With These Top 5 Value Picks (Nov 21)

Amazon

American Express

Occidental Petroleum

StoneCo

These Buffett stocks adhere to the Oracle of Omaha's investment philosophy and trade at levels that should continue to attract new buyers.

5 Warren Buffett Stocks Investors Should Add to Their Portfolios

Biogen

Celgene

Edwards Lifesciences

HCA Healthcare

Incyte

Pfizer

Teleflex

Health Care Select Sector SPDR Fund

DENTSPLY SIRONA

These are the health care stocks with the best value, fastest growth, and most momentum for November.

Top Health Care Stocks for November 2019

DaVita HealthCare (DVA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Why DaVita HealthCare (DVA) Might be Well Poised for a Surge

Constellation Pharmaceuticals Inc

Boingo Wireless

Why Boingo Wireless, DaVita, and Constellation Pharmaceuticals Jumped Today

The dialysis company is generating cash and becoming more efficient.

Here's Why DaVita Stock Jumped Today

DaVita (DVA) raises guidance for 2019 following impressive Q3 results.

DaVita (DVA) Earnings and Revenues Beat Estimates in Q3

DaVita Inc. (DVA) CEO Javier Rodriguez on Q3 2019 Results - Earnings Call Transcript

DaVita HealthCare (DVA) delivered earnings and revenue surprises of 24.39% and 1.81%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

DaVita HealthCare (DVA) Surpasses Q3 Earnings and Revenue Estimates

Legendary short-seller Jim Chanos of Kynikos Associates on Thursday announced his fund has taken a short position in kidney-dialysis company DaVita Inc.

Jim Chanos unveils short position in kidney-dialysis firm DaVita

Jim Chanos, founder of Kynikos Associates, revealed Thursday a stock he has been shorting for years: kidney dialysis company DaVita.

Jim Chanos says he's short kidney dialysis company DaVita

Canadian Solar

General Motors

Hibbett Sports

MetLife

P/B ratio is emerging as a convenient tool for identifying low-priced stocks that have high growth prospects.

5 Low Price-to-Book Stocks to Increase Your Portfolio's Value

Guess?

Goldman Sachs

While P/E alone fails to identify a true value stock, PEG helps find the intrinsic value of a stock.

5 Buffett-Style Value Picks Boasting Impressive PEG Ratio

Southwest Airlines

Moody's

Bridgewater co-CIO has holdings in line with Buffett’s 'good companies' strategy.

3 Predictable Stocks Warren Buffett and Ray Dalio Agree On

Arbor Realty Trust

Chemed

Viad Corp

Exantas Capital Corp

The ISM Services index clearly reflects that the U.S. economy has sustained its momentum despite heightened trade conflict and global economic slowdown.

Strong ISM Services Index Eases Recession Fears: 5 Top Picks

Alexion Pharma

Rush Enterprises

5 Price-to-Book Value Picks for September

DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock?

Why Is DaVita HealthCare (DVA) Down 5% Since Last Earnings Report?

Clean Harbors

Luna Innovations

Dr. Reddy's Labs

We have shortlisted solid stocks from the top-performing sectors in Q2 that should make a great addition to your portfolio.

5 Stocks From the Best Performing Sectors in Q2

Centene

Illumina

UnitedHealth Group

Andreas Halvorsen (Trades, Portfolio), founding partner and chief investment officer of Viking Global Investors, bought shares of the following stocks in both the first and second quarters.

Andreas Halvorsen Keeps Buying Centene, DaVita and more.

DaVita (DVA) continues to benefit from international expansion, strategic buyouts and strong demand of dialysis services.

Here's Why You Should Invest in DaVita (DVA) Stock For Now

Let's see if DaVita (DVA) stock is a good choice for value-oriented investors right now from multiple angles.

Is DaVita (DVA) a Profitable Stock for Value Investors Now?

Mix Telematics

SYNNEX

5 Price-to-Book Value Picks to Improve Portfolio Returns

Alamos Gold

Franco-Nevada C

iStar Inc

Throughout this month, U.S. stock markets are witnessing extreme volatility.

5 Safe Picks Amid Yield Inversion and Geopolitical Concerns

DaVita recently completed the sale of various hospital assets (DaVita Medical Group) to UnitedHealthcare.

Large Buyback At DaVita Should Create Upside

News for DaVita Stock (DVA)